US Food and Drug Administration

U.S. approval of Merck cancer immunotherapy expected soon

U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

Read Full Article

California healthcare informatics firm AdverseEvents secures $2M in Series A round

Santa Rosa, US-based healthcare informatics firm AdverseEvents secured $2 million in its Series A funding round led by London, UK-based life science research firm Evaluate Ltd to accelerate its growth.

Read Full Article

Blue Ocean invests $5M in Colorado dental firm St Renatus

Investment management firm Blue Ocean invested $5 million in Fort Collins, Colorado-based dental firm St Renatus for the latter's drug application for its needle-free anesthetic.

Read Full Article

Google-backed 23andMe Inc's row with regulators leads to strict oversight of personal gene tests- report

The row that occurred between 23andMe Inc and the Food and Drug Administration has led to stricter oversight of the genetic testing industry, according to a Bloomberg report.

Read Full Article

AstraZeneca acquires Omthera Pharmaceuticals

AstraZeneca acquired Omthera Pharmaceuticals.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics